Skip to Content

Chromosome Cure

Every human cell carries 46 chromosomes, the DNA-and-protein packages that transmit genes from generation to generation as cells divide. Lately, scientists have been wondering whether they can fool the machinery of the cell by inserting a synthetic 47th chromosome furnished with genes of their own choosing. Two companies, Athersys in Cleveland, OH, and Chromos Molecular Systems in Burnaby, British Columbia, are beginning to find an answer; they are testing artificial chromosomes as a safe and effective way to introduce therapeutic genes into patients suffering from deadly genetic disorders.

Their hope is that the fake chromosomes will provide a viable alternative to conventional gene therapy, which typically uses viruses to deliver gene replacements in treatment of such diseases as hemophilia and cystic fibrosis. The small size of the viruses limits the number of genes that can be delivered, and because the viral proteins can also cause dangerous immune reactions, the strategy is risky. Artificial chromosomes might spare gene therapy patients from these problems. An artificial chromosome can carry any number of genes, is ignored by the immune system, and functions independently of other chromosomes, so the technique “represents potentially a response or an answer to those challenges,” says Huntington F. Willard, director of the Duke University Institute for Genome Sciences and Policy. Willard and Athersys researchers created the first human artificial chromosomes five years ago.

Now Athersys and Chromos are trying to prove Willard right. In experiments on mice, Chromos has demonstrated that the bogus chromosomes are transmitted from mother cells to daughter cells during cell division and from one generation to the next as animals reproduce. More recently, Chromos scientists proved that they can raise red blood cell counts in mice by injecting cells that contain artificial chromosomes bearing the gene for erythropoeitin, a protein that stimulates blood cell production. If similar constructs work in humans, the company’s potential targets include diabetes, hemophilia, and various metabolic disorders.

Willard anticipates that human trials are a year or more in the future. But skeptics abound. Michle Calos, a Stanford University geneticist who previously had worked with artificial chromosomes, has since shifted her focus to other gene-therapy methods such as inserting therapeutic genes at specific places on natural chromosomes. Says Calos, “I’m not sure that that approach will make it to the clinic, because I think there might be alternatives that are just more competitive.”

Keep Reading

Most Popular

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.